First of all, contracting with C14 is a business transaction - not an "outcome". If BIT has that contract with a consultant as their only positive outcome, then they are truly going down the drain.
What they don't have as an achievement is the ability to have a very positive trial result nor anything that has sparked interest in a third party.
The complete failure of the COVID trial i a terminal blow given the amount of hype generated by BIT - and the thousands of posts by rampers including hundreds of posts about COVID generated on this forum. A trial where the placebo had a better effect on participants i a very bad look.
The incredible delay in releasing the HIV trial results was nothing less than fishy. Then to release the results with no changes from the previous P2 trial was tantamount to a failed trial. After promising that a "cure" was possible, the results were met with complete silence from the Biotech world - with no signs that will change.
How is C14 going to materially change that? Guess we will know in the next few months.
Unless something changes materially by mid year, then the whole kit and kaboodle will sink like a stone. Any CR will only extend the life of the company for another six months. The auditors will have a field day.
Apart from all that, BIT is apparently not undertaking any real research. Not surprising I suppose when you consider there are no funds left to do any research - and without the promise of any R&D funding, even the loan sharks won't touch BIT.
BIT Price at posting:
1.5¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)